China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced a partnership with compatriot firm GeneQuantum Healthcare (Suzhou) Co., Ltd in relation to antibody-drug conjugate (ADC) development. The collaboration aims to advance the development and commercial production of a new generation of ADCs for global customers.
Partnership Details and Technology Platforms
As per the agreement, WuXi XDC will actively expand and promote the bio enzyme solid phase catalytic continuous coupling technology platforms iLDC and iGDC independently developed by GeneQuantum worldwide. These platforms enable the development and commercial production of innovative ADCs. GeneQuantum will also develop a number of innovative ADC drugs based on the advanced antibody coupling drug production technology platform of WuXi XDC and the integrated CMC capability to accelerate the process of product commercialization.
Company Backgrounds and Capabilities
GeneQuantum, a global innovative biopharmaceutical company, boasts iLDC and iGDC, underlying technology systems for ADC development and manufacturing. WuXi XDC, meanwhile, has a robust pipeline with 270 ongoing or completed programs as of September 30, 2022, including 29 filed for INDs and 8 at Phase II/III stages. This partnership positions both companies to leverage their respective strengths in ADC development and production, driving innovation and accelerating the commercialization of next-generation ADCs.-Fineline Info & Tech
